Return to homepagePandemic Pact

ACTT-DMID20-0006/INSIGHT-010

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-164

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Not provided Not provided

  • Research Location

    United Kingdom

  • Lead Research Institution

    MRC Clinical Trials Unit at UCL

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The Adaptive COVID-19 Treatment Trial (ACTT) aims to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. One of the earliest treatments arms - antiviral drug remdesivir - was fast tracked into the clinic after Stage 1 results reported in May 2020. Results from Stage 2 were published in December 2020 and combination of remdesivir and baricitinib given emergency use authorisation by the FDA. While new treatments are being tested in Stage 2, the ACTT trial itself will instead continue under a new master protocol; ACTIV-3 (INSIGHT-14).